Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Activating mutations in <i>Kirsten rat sarcoma viral oncogene homologue (KRAS)</i>, in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC). Several agents targ...

Full description

Bibliographic Details
Main Authors:	Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, Paul F. Wheatley-Price, Stephen Yip, Barbara L. Melosky
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Current Oncology
Subjects:	KRAS G12C NSCLC targeted therapy immune checkpoint inhibitors mutation testing resistance
Online Access:	https://www.mdpi.com/1718-7729/30/7/476

Similar Items

Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLC
by: Parneet K. Cheema, et al.
Published: (2021-11-01)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
by: Francis Proulx-Rocray, et al.
Published: (2023-01-01)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01)

KRAS in NSCLC: State of the Art and Future Perspectives
by: Priscilla Cascetta, et al.
Published: (2022-11-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
by: Kathryn C. Arbour, MD, et al.
Published: (2022-01-01)

KRAS G12C Mutations in NSCLC: From Target to Resistance
by: Alfredo Addeo, et al.
Published: (2021-05-01)

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
by: Diana N. Ionescu, et al.
Published: (2022-07-01)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
by: Kira-Lee Koster, et al.
Published: (2022-08-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)

WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc
by: Chen Wu, et al.
Published: (2015-01-01)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
by: Alessandro Inno, et al.
Published: (2023-06-01)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
by: Martin Rupp, et al.
Published: (2023-07-01)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
by: Gu Xiaodong, et al.
Published: (2023-03-01)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
by: Anne-Marie Ruppert, MD, PhD, et al.
Published: (2020-09-01)

Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
by: Maria Francesca Alvisi, et al.
Published: (2020-07-01)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
by: Marc Cucurull, et al.
Published: (2022-01-01)

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
by: Barbara L. Melosky, et al.
Published: (2023-06-01)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
by: Francesca Jacobs, et al.
Published: (2021-12-01)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
by: Hanxiao Chen, et al.
Published: (2022-10-01)

Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings
by: Milena Pązik, et al.
Published: (2021-02-01)

Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
by: Juliana F. Vilachã, et al.
Published: (2020-08-01)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
by: Alice Indini, et al.
Published: (2021-05-01)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
by: Mo Shen, et al.
Published: (2022-01-01)

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
by: Liang Hong, et al.
Published: (2012-04-01)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
by: Saveri Bhattacharya, et al.
Published: (2015-12-01)

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
by: Cian O’Leary, et al.
Published: (2023-11-01)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
by: Barbara Melosky, et al.
Published: (2021-11-01)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
by: Biagio Ricciuti, et al.
Published: (2022-11-01)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
by: Anand Khadse, et al.
Published: (2022-04-01)

Targeting KRAS in Non-Small Cell Lung Cancer
by: Elena Corral de la Fuente, et al.
Published: (2022-01-01)

TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLC
by: Salvina Laura Tammaccaro, et al.
Published: (2023-04-01)

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
by: Jonathan W. Goldman, et al.
Published: (2020-10-01)

Targeting KRAS: The Elephant in the Room of Epithelial Cancers
by: Valeria Merz, et al.
Published: (2021-03-01)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
by: Éabha O’Sullivan, et al.
Published: (2023-03-01)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
by: Ullas Batra, et al.
Published: (2023-02-01)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
by: Meng Xia, et al.
Published: (2021-01-01)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023-01-01)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
by: Enrico Gurreri, et al.
Published: (2023-05-01)

Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a <i>KRAS</i> G12C Mutation: A Real-World Study
by: Oliver Illini, et al.
Published: (2022-07-01)